Mochida Pharmaceutical (TSE:4534) reported a net profit margin of 5.7%, up from 4.3% a year earlier, with earnings surging 36.5% over the past year. Despite this progress, shares currently trade at ¥3 ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.57 per share a year ago.

In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $8.13 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $6.61 per share a year ago. These ...

Discover key Royalty Pharma Q3 2025 earnings insights—double-digit growth, new acquisitions, and raised guidance for investors.

The FDA announced it will relax certain rules for approving low-cost versions of some high-priced medications.

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid guidance for 2025.

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

Ho next-generation AI-driven traceability hubs can transform pharmaceutical serialization from a compliance requirement into a business advantage, while enabling real-time supply chain visibility, ...

Data from Storyful found that users’ fears around AI in the therapy space are widespread. The report noted that one user on Reddit called AI driven therapy a “control system,” while others warned of ...

Marking a significant milestone in its Asian growth strategy, Clariant (Muttenz, Switzerland; has unveiled its newly expanded ...